Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)

被引：1
|
作者：
Mukohara, Toru
Ozaki, Yukinori
Kitano, Shigehisa
Yamashita, Makiko
Ikarashi, Daiki
Tsurutani, Junji
Iwasa, Tsutomu
Takahashi, Masato
Masuda, Norikazu
Futamura, Manabu
Minami, Hironobu
Matsumoto, Koji
Tanabe, Yuko
Kawabata, Hidetaka
Yoshimura, Kenichi
Takano, Toshimi
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P5-02-42
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-02-42
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Nivolumab plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer-regional differences in efficacy
    Mehta, Rutika
    Shah, Manish A.
    ANNALS OF PALLIATIVE MEDICINE, 2022,
  • [22] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wang, Wei
    Lei, Wenqian
    Fang, Ziru
    Jiang, Ruiyuan
    Wang, Xiaojia
    BMC CANCER, 2024, 24 (01)
  • [23] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wei Wang
    Wenqian Lei
    Ziru Fang
    Ruiyuan Jiang
    Xiaojia Wang
    BMC Cancer, 24
  • [24] Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
    Zhengwu Sun
    Xiaoyan Lan
    Shizhao Xu
    Shen Li
    Yalin Xi
    BMC Cancer, 20
  • [25] Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
    Sun, Zhengwu
    Lan, Xiaoyan
    Xu, Shizhao
    Li, Shen
    Xi, Yalin
    BMC CANCER, 2020, 20 (01)
  • [26] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    FUTURE ONCOLOGY, 2023, : 727 - 736
  • [27] Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
    Christoph Zielinski
    Istvan Lang
    Semir Beslija
    Zsuzsanna Kahan
    Moshe J Inbar
    Salomon M Stemmer
    Rodica Anghel
    Damir Vrbanec
    Diethelm Messinger
    Thomas Brodowicz
    British Journal of Cancer, 2016, 114 : 163 - 170
  • [28] Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR
    Wang, Rong
    Zhu, Qiao-Yan
    Ye, Wei-Wu
    Huang, Yuan
    Chen, Zhan-Hong
    Zheng, Ya-Bing
    Zou, Xiao
    Wang, Jian
    Jiang, Dan-Lu
    Wang, Xiao-Jia
    Xu, Zheng-Yang
    Cao, Wen-Ming
    DISCOVERY MEDICINE, 2024, 36 (182) : 527 - 537
  • [29] Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
    Montagna, Emilia
    Cancello, Giuseppe
    Bagnardi, Vincenzo
    Pastrello, Davide
    Dellapasqua, Silvia
    Perri, Gino
    Viale, Giuseppe
    Veronesi, Paolo
    Luini, Alberto
    Intra, Mattia
    Calleri, Angelica
    Rampinelli, Cristiano
    Goldhirsch, Aron
    Bertolini, Francesco
    Colleoni, Marco
    CLINICAL BREAST CANCER, 2012, 12 (03) : 207 - 214
  • [30] Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.
    Shimozaki, Keitaro
    Fukuda, Koshiro
    Ooki, Akira
    Nakayama, Izuma
    Yoshino, Koichiro
    Udagawa, Shohei
    Fukuoka, Shota
    Osumi, Hiroki
    Ogura, Mariko
    Wakatsuki, Takeru
    Takahari, Daisuke
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 341 - 341
12345